T1	Participants 564 583	Thirty-one subjects
T2	Participants 771 778	placebo
T3	Participants 737 748	raltegravir
T4	Participants 957 974	raltegravir group
T5	Participants 1049 1063	placebo group.
T6	Participants 1312 1319	placebo
T7	Participants 1344 1355	Raltegravir
